From Yahoo Finance: 2025-05-14 08:51:00

Private equity firms Carlyle Group and SK Capital Partners have increased their offer to acquire gene therapy maker bluebird bio to $5 per share upfront, up from $3 per share with a contingent value right (CVR) of $6.84. The new bid could total about $49 million. Bluebird’s board unanimously approved the deal, urging shareholders to tender their shares. The company has faced financial challenges, laying off employees and focusing on launching gene therapies like Lyfgenia for sickle cell disease. In March, bluebird received a non-binding bid from Ayrmid, but no binding offer was made.



Read more at Yahoo Finance: Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital